Cancer Drug Responses Asheville NC

new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Mridu S Chand
(828) 253-4262
445 Biltmore Ave
Asheville, NC
Specialty
Internal Medicine, Hematology / Oncology

Data Provided by:
Orren Beaty, DO
(828) 213-5770
50 Doctors Dr
Asheville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Kirksville Coll Of Osteo Med, Kirksville Mo 63501
Graduation Year: 1988

Data Provided by:
Paul Michael Ahearne, MD
(828) 350-7515
131 McDowell St Ste 100
Asheville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Duke Univ Sch Of Med, Durham Nc 27710
Graduation Year: 1988

Data Provided by:
Quinten Curtis Black, MD
(828) 253-7077
445 Biltmore Ave Ste G102
Asheville, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Tulane Univ Sch Of Med, New Orleans La 70112
Graduation Year: 1998

Data Provided by:
Timothy Mark Davis, MD
(828) 254-8232
1 Doctors Dr
Asheville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Va Sch Of Med, Charlottesville Va 22908
Graduation Year: 1986

Data Provided by:
Orren Beaty III, DO
(828) 213-1740
50 Doctors Dr Ste 105
Asheville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Kirksville Coll Of Osteo Med, Kirksville Mo 63501
Graduation Year: 1988

Data Provided by:
Robert Carr Moffatt, MD
(828) 258-2464
86 Victoria Rd
Asheville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Tn, Memphis, Coll Of Med, Memphis Tn 38163
Graduation Year: 1957
Hospital
Hospital: St Josephs Hospital, Asheville, Nc
Group Practice: Western Surgical Ctr

Data Provided by:
Brian P Quaranta
(828) 253-7077
445 Biltmore Ave
Asheville, NC
Specialty
Radiation Oncology

Data Provided by:
Michael Joseph Messino
(828) 253-4262
445 Biltmore Ave
Asheville, NC
Specialty
Medical Oncology

Data Provided by:
Barton Riley Paschal, MD
(828) 254-8232
1 Doctors Dr
Asheville, NC
Specialties
Oncology (Cancer), Hematology-Internal Medicine
Gender
Male
Education
Medical School: Emory Univ Sch Of Med, Atlanta Ga 30322
Graduation Year: 1976
Hospital
Hospital: Park Ridge Hospital, Fletcher, Nc; Mission St Joseph Health Syste, Asheville, Nc; St Josephs Hospital, Asheville, Nc
Group Practice: Asheville Hematology Oncology Assoc Pa; Asheville Hematology Oncology Associates Pa

Data Provided by:
Data Provided by:

Cancer Drug Responses

Provided By:

A new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Avastin, which shrinks tumors by cutting off their blood supply, was approved this spring by the U.S. Food and Drug Administration for treatment of aggressive brain cancer. However, half of those with the cancer don't respond to the drug, which can cost up to $10,000 a month, according to a news release from the University of California, Los Angeles.

UCLA researchers examined 82 people who had surgery and radiation to treat glioblastoma, the most common and deadly form of adult brain cancer. Half of them were given infusions of Avastin every two weeks, and all had monthly MRI brain scans to monitor changes.

An analysis of the scans showed that there was greater water movement in the tumors of people who later had the best response to Avastin. By using MRI to measure the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which tumors would progress within six months and which would not.

Increased water movement in tumors is linked with higher levels of a growth factor called VEGF, which is secreted by a tumor to promote the growth of new blood vessels that provide the tumor with oxygen and nutrients. Avastin blocks VEGF, the researchers explained.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," lead author Dr. Whitney Pope, assistant professor of radiological sciences at UCLA's David Geffen School of Medicine, said in the news release.

"We were correct 70 percent of the time," Pope said. "Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The study appears in the July issue of Radiology.

"Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," Pope said.

He and a co-author are consultants for Genentech, which makes Avastin, and are working with the company on several research studies.

More information

The U.S. National Cancer Institute has more about brain tumors.

SOURCE: University of California, Los Angeles, news release, July 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com